<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Med Insights Circ Respir Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Med Insights Circ Respir Pulm Med</journal-id><journal-id journal-id-type="publisher-id">CRA</journal-id><journal-id journal-id-type="hwp">spcra</journal-id><journal-title-group><journal-title>Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1179-5484</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5987896</article-id><article-id pub-id-type="doi">10.1177/1179548418771702</article-id><article-id pub-id-type="publisher-id">10.1177_1179548418771702</article-id><article-id pub-id-type="publisher-manuscript">CRA-17-0003.R1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yasui</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Inui</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref><xref ref-type="corresp" rid="corresp1-1179548418771702"/></contrib><contrib contrib-type="author"><name><surname>Fujisawa</surname><given-names>Tomoyuki</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Karayama</surname><given-names>Masato</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Enomoto</surname><given-names>Noriyuki</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Yutaro</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Kuroishi</surname><given-names>Shigeki</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Ohba</surname><given-names>Hisano</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Yokomura</surname><given-names>Koshi</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Masaki</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Koshimizu</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Toyoshima</surname><given-names>Mikio</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>Masafumi</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Shirai</surname><given-names>Toshihiro</given-names></name><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib><contrib contrib-type="author"><name><surname>Suda</surname><given-names>Takafumi</given-names></name><xref ref-type="aff" rid="aff1-1179548418771702">1</xref><xref ref-type="aff" rid="aff2-1179548418771702">2</xref></contrib></contrib-group><aff id="aff1-1179548418771702"><label>1</label>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan</aff><aff id="aff2-1179548418771702"><label>2</label>Hamamatsu Shizuoka Respiratory Group, Hamamatsu, Japan</aff><author-notes><corresp id="corresp1-1179548418771702">Naoki Inui, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. Email: <email>inui@hama-med.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>12</volume><elocation-id>1179548418771702</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>Inhaled corticosteroids are widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, their use has been questioned for appropriate dose and a possible increased risk of pneumonia. Here, we reviewed patients with COPD who had received fluticasone&#x02013;salmeterol combination treatment using data from a linked electronic medical record database. A total of 180 patients received salmeterol with 250&#x02009;&#x000b5;g fluticasone propionate twice daily and 78 received salmeterol and 100&#x02009;&#x000b5;g fluticasone propionate twice daily. In both groups, there was no difference in the improved forced expiratory volume in 1&#x02009;second and COPD assessment test score and the proportion of patients with exacerbations. Although the incidence of common toxicity was approximately equal, that of pneumonia was much higher in the 250&#x02009;&#x000b5;g group (8.9% vs 1.3%, <italic>P</italic>=.01). The beneficial effects of inhaled corticosteroids might be obtained at lower doses.</p></abstract><kwd-group><kwd>Chronic obstructive pulmonary disease</kwd><kwd>exacerbation</kwd><kwd>fluticasone&#x02013;salmeterol</kwd><kwd>inhaled corticosteroid</kwd><kwd>pneumonia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1179548418771702"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide.<sup><xref rid="bibr1-1179548418771702" ref-type="bibr">1</xref></sup> It is characterized by airflow limitation and is commonly associated with accelerated lung function decline over time.<sup><xref rid="bibr2-1179548418771702" ref-type="bibr">2</xref><xref rid="bibr3-1179548418771702" ref-type="bibr"/><xref rid="bibr4-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr5-1179548418771702" ref-type="bibr">5</xref></sup> At present, pharmacotherapy with inhaled bronchodilators, anticholinergics and &#x003b2;<sub><xref rid="bibr2-1179548418771702" ref-type="bibr">2</xref></sub> agonists, alone or in combination, is the mainstay of COPD treatment,<sup><xref rid="bibr2-1179548418771702" ref-type="bibr">2</xref>,<xref rid="bibr3-1179548418771702" ref-type="bibr">3</xref></sup> and inhaled corticosteroids are also widely used. In a landmark study, Towards a Revolution in COPD Health (TORCH), combination treatment with fluticasone&#x02013;salmeterol was shown to improve pulmonary function, symptoms, and health status and reduce exacerbations.<sup><xref rid="bibr6-1179548418771702" ref-type="bibr">6</xref></sup> Because exacerbations accelerate lung function decline, cause a deterioration in health status, and increase the risk of death,<sup><xref rid="bibr4-1179548418771702" ref-type="bibr">4</xref>,<xref rid="bibr7-1179548418771702" ref-type="bibr">7</xref><xref rid="bibr8-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr9-1179548418771702" ref-type="bibr">9</xref></sup> preventing them is a priority. A systematic review using the Cochrane Airways Group Specialized Register concluded that inhaled corticosteroids reduced the rate of exacerbation and deterioration in quality of life.<sup><xref rid="bibr10-1179548418771702" ref-type="bibr">10</xref></sup> In consensus guidelines, inhaled corticosteroids are particularly recommended in severe cases of COPD with a history of exacerbations.<sup><xref rid="bibr3-1179548418771702" ref-type="bibr">3</xref><xref rid="bibr4-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr5-1179548418771702" ref-type="bibr">5</xref></sup></p><p>The use of inhaled corticosteroids for COPD treatment has been increasing in recent years,<sup><xref rid="bibr12-1179548418771702" ref-type="bibr">11,12</xref></sup> but concerns have been raised. First, the dose&#x02013;response relationship of inhaled corticosteroids remains unknown in COPD. In the treatment of asthma, the efficacy of inhaled corticosteroids is dose-dependent and the dose of the corticosteroid is chosen according to disease severity. Although 500&#x02009;&#x000b5;g fluticasone propionate in combination with 50&#x02009;&#x000b5;g salmeterol in a single inhaler twice daily is commonly used for COPD worldwide, few studies have systematically investigated appropriate doses for this indication. A meta-analysis of 7 randomized trials reported that treatment with inhaled corticosteroids led to a 25% reduction in all-cause mortality,<sup><xref rid="bibr13-1179548418771702" ref-type="bibr">13</xref></sup> but fluticasone propionate equivalent doses ranged from 400 to 1000&#x02009;&#x000b5;g/d and no dose&#x02013;response relationship was apparent. In addition, some clinical studies have demonstrated improvements in lung function, symptom control, and exacerbations by adding inhaled corticosteroids at a lower dose, equivalent to 250&#x02009;&#x000b5;g fluticasone propionate.<sup><xref rid="bibr14-1179548418771702" ref-type="bibr">14</xref><xref rid="bibr15-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr16-1179548418771702" ref-type="bibr">16</xref></sup> It is possible that even lower doses of fluticasone propionate will be effective in the treatment of COPD.</p><p>Second, the safety of inhaled corticosteroids in COPD remains debated. Long-term treatment with inhaled corticosteroids has been associated with side effects in patients with COPD. In particular, the risk of pneumonia has been the focus of research attention. In randomized controlled trials, fluticasone&#x02013;salmeterol has been linked with increases in the incidence of pneumonia compared with alternative bronchodilator regimens.<sup><xref rid="bibr6-1179548418771702" ref-type="bibr">6</xref>,<xref rid="bibr17-1179548418771702" ref-type="bibr">17</xref></sup> A large observational study identified an increase in the incidence of hospitalizations for pneumonia and of pneumonia hospitalization followed by death within 30&#x02009;days.<sup><xref rid="bibr18-1179548418771702" ref-type="bibr">18</xref></sup> There was a correlation between the dose of inhaled corticosteroids and the risk of pneumonia, with a high rate of pneumonia in those taking high-dose inhaled corticosteroids, equivalent to fluticasone propionate at 1000&#x02009;&#x000b5;g/d or more. In particular, there was a dose-dependent risk of pneumonia in COPD patients treated with fluticasone propionate.<sup><xref rid="bibr19-1179548418771702" ref-type="bibr">19</xref>,<xref rid="bibr20-1179548418771702" ref-type="bibr">20</xref></sup> It is therefore important to examine the efficacy and safety of low-dose fluticasone propionate in combination with salmeterol in patients with COPD.</p><p>In Japan, patients receive twice daily fluticasone&#x02013;salmeterol at 2 different doses, 100 or 250&#x02009;&#x000b5;g (usual dosage provided in the package insert in Japan), at the discretion of the treating physician. We hypothesized that lower doses of inhaled fluticasone with salmeterol will show similar efficacy to usual dosage of fluticasone propionate. Here, we retrospectively compared the efficacy and safety of these 2 doses of fluticasone propionate in combination with salmeterol twice daily.</p></sec><sec sec-type="methods" id="section2-1179548418771702"><title>Methods</title><sec id="section3-1179548418771702"><title>Study design and patients</title><p>This was a retrospective observational study conducted in accordance with the ethical standards described in the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Hamamatsu University School of Medicine (certificate #25-302). Because of the retrospective manner of the study, written consent from participants for use of records was waived. All patient records/information were anonymized and de-identified prior to analysis. The study was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN ID000013490).</p><p>Using linked electronic medical records from 2011 and 2012, we obtained data from patients with COPD who had received fluticasone&#x02013;salmeterol combination (dry powder inhaler) treatment for 1&#x02009;year and had undergone examinations before treatment and after 1&#x02009;year of treatment. Diagnosis and classification of COPD were based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 classification.<sup><xref rid="bibr4-1179548418771702" ref-type="bibr">4</xref></sup> Bronchial asthma was strictly excluded by pulmonary specialists.</p></sec><sec id="section4-1179548418771702"><title>Measurement of pulmonary function</title><p>Pulmonary function tests (forced vital capacity [FVC], forced expiratory volume in 1&#x02009;second [FEV<sub>1</sub>], and inspiratory capacity) were performed using an electric spirometer. FEV<sub>1</sub> was expressed as a percentage of predicted values according to the prediction equations of the Japanese Respiratory Society.<sup><xref rid="bibr21-1179548418771702" ref-type="bibr">21</xref></sup> Symptoms and health status were assessed using the COPD assessment test (CAT).</p></sec><sec id="section5-1179548418771702"><title>Definition of exacerbation and pneumonia</title><p>The COPD exacerbations were defined as events that required additional pharmacological treatment (systemic glucocorticoids, antibiotics, or both).<sup><xref rid="bibr4-1179548418771702" ref-type="bibr">4</xref>,<xref rid="bibr6-1179548418771702" ref-type="bibr">6</xref>,<xref rid="bibr22-1179548418771702" ref-type="bibr">22</xref></sup> Diagnosis of pneumonia was based on new-onset respiratory symptoms and infiltration on chest X-ray or computed tomography.</p></sec><sec id="section6-1179548418771702"><title>Statistical analysis</title><p>The Wilcoxon matched-pair signed-rank test and Mann&#x02013;Whitney <italic>U</italic> test were used for continuous variables, and the chi-square test was used for categorical groups. Data are presented as number (percentage) or median (range). Univariate and multivariate logistic regression analyses were performed to identify the risk factors for developing pneumonia. JMP9.0.0 (SAS Institute Japan, Tokyo, Japan) was used for statistical analysis and <italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 was considered significant.</p></sec></sec><sec sec-type="results" id="section7-1179548418771702"><title>Results</title><sec id="section8-1179548418771702"><title>Patient characteristics</title><p>A total of 372 patients with COPD received fluticasone&#x02013;salmeterol inhaler. Among them, 258 patients completed examinations before treatment and after 1&#x02009;year of treatment. The median age was 76 (47-94) years. All patients had a history of smoking (median pack-year, 50.0) and 36 patients (14.0%) were current smokers. The median predicted FEV<sub>1</sub> was 56.1% (20.0%-143.2%). The percentages of patients at GOLD classification stages I, II, III, and IV were 7.7%, 51.2%, 32.2%, and 8.9%, respectively. The CAT score was 13 (1-35). Sixty-nine patients (26.7%) had a history of exacerbation during the previous year. The proportions of the GOLD combined COPD assessment grades consisting of symptoms, airflow obstruction, and exacerbation history based on 2011 GOLD report<sup><xref rid="bibr4-1179548418771702" ref-type="bibr">4</xref></sup> were 52 (20.2%) in grade A, 109 (42.2%) in grade B, 20 (7.8%) in grade C, and 77 (29.8%) in grade D. Two hundred (77.5%) patients had also received a long-acting muscarinic antagonist.</p><p>Among 258 patients receiving fluticasone&#x02013;salmeterol, 180 (70.0%) received fluticasone propionate at a dose of 250&#x02009;&#x000b5;g twice daily (fluticasone 250&#x02009;&#x000b5;g group) and 78 patients (30.0%) received fluticasone propionate 100&#x02009;&#x000b5;g twice daily (fluticasone 100&#x02009;&#x000b5;g group). <xref ref-type="table" rid="table1-1179548418771702">Table 1</xref> shows the characteristics of patients in each group. Baseline smoking habits, pulmonary function tests, and CAT score were comparable between the 2 groups. Approximately a quarter of patients in each group had a history of exacerbations in the previous year.</p><table-wrap id="table1-1179548418771702" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_1179548418771702-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Fluticasone propionate 100&#x02009;&#x000b5;g and salmeterol</th><th align="center" rowspan="1" colspan="1">Fluticasone propionate 250&#x02009;&#x000b5;g and salmeterol</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number of patients</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">180</td></tr><tr><td rowspan="1" colspan="1">Age, y (range)</td><td rowspan="1" colspan="1">76 (54&#x02013;94)</td><td rowspan="1" colspan="1">75 (47&#x02013;92)</td></tr><tr><td rowspan="1" colspan="1">Male (%)</td><td rowspan="1" colspan="1">73 (93.6%)</td><td rowspan="1" colspan="1">167 (92.8%)</td></tr><tr><td rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">21.0 (13.6&#x02013;32.2)</td><td rowspan="1" colspan="1">21.0 (13.2&#x02013;34.9)</td></tr><tr><td colspan="3" rowspan="1">Smoking status</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Current smoker (%)</td><td rowspan="1" colspan="1">13 (16.7%)</td><td rowspan="1" colspan="1">23 (12.8%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pack-years (range)</td><td rowspan="1" colspan="1">50 (20&#x02013;186)</td><td rowspan="1" colspan="1">50 (20&#x02013;200)</td></tr><tr><td colspan="3" rowspan="1">Lung function</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FVC (L)</td><td rowspan="1" colspan="1">2.64 (1.23&#x02013;4.12)</td><td rowspan="1" colspan="1">2.54 (1.21&#x02013;4.84)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub> (L)</td><td rowspan="1" colspan="1">1.18 (0.63&#x02013;2.04)</td><td rowspan="1" colspan="1">1.16 (0.4&#x02013;2.85)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub> % predicted (%)</td><td rowspan="1" colspan="1">56.9 (23.1&#x02013;143.2)</td><td rowspan="1" colspan="1">55.1 (20.0&#x02013;122.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC (%)</td><td rowspan="1" colspan="1">46.1 (27.5&#x02013;69.5)</td><td rowspan="1" colspan="1">46.0 (17.9&#x02013;68.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Inspiratory capacity (L)</td><td rowspan="1" colspan="1">1.77 (0.87&#x02013;3.08)</td><td rowspan="1" colspan="1">1.77 (0.31&#x02013;3.72)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CAT score</td><td rowspan="1" colspan="1">11 (1&#x02013;35)</td><td rowspan="1" colspan="1">13 (2&#x02013;33)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Patients with any exacerbations in the previous year</td><td rowspan="1" colspan="1">22 (28.2%)</td><td rowspan="1" colspan="1">47 (26.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Patients with severe exacerbations in the previous year</td><td rowspan="1" colspan="1">6 (7.7%)</td><td rowspan="1" colspan="1">16 (8.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Patients receiving long-acting muscarinic antagonist</td><td rowspan="1" colspan="1">61 (78.2%)</td><td rowspan="1" colspan="1">139 (77.2%)</td></tr><tr><td colspan="3" rowspan="1">Combined COPD assessment<sup><xref ref-type="table-fn" rid="table-fn3-1179548418771702">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Group A</td><td rowspan="1" colspan="1">15 (19.2%)</td><td rowspan="1" colspan="1">37 (20.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Group B</td><td rowspan="1" colspan="1">31 (39.7%)</td><td rowspan="1" colspan="1">78 (43.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Group C</td><td rowspan="1" colspan="1">9 (11.5%)</td><td rowspan="1" colspan="1">11 (6.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Group D</td><td rowspan="1" colspan="1">23 (29.5%)</td><td rowspan="1" colspan="1">54 (30.0%)</td></tr><tr><td colspan="3" rowspan="1">Comorbidity</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypertension</td><td rowspan="1" colspan="1">18 (23.1%)</td><td rowspan="1" colspan="1">60 (33.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td rowspan="1" colspan="1">4 (5.1%)</td><td rowspan="1" colspan="1">26 (14.4%)<xref ref-type="table-fn" rid="table-fn4-1179548418771702">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chronic heart failure</td><td rowspan="1" colspan="1">14 (17.9%)</td><td rowspan="1" colspan="1">28 (15.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chronic kidney disease</td><td rowspan="1" colspan="1">3 (3.8%)</td><td rowspan="1" colspan="1">6 (3.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Benign prostatic hyperplasia</td><td rowspan="1" colspan="1">12 (15.4%)</td><td rowspan="1" colspan="1">16 (8.9%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1179548418771702"><p>Abbreviations: CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1&#x02009;second; FVC, forced vital capacity.</p></fn><fn id="table-fn2-1179548418771702"><p>Data are expressed as number (percentage) or median (range).</p></fn><fn id="table-fn3-1179548418771702"><label>a</label><p>Combined COPD assessment proposed by Global Initiative for Chronic Obstructive Lung Disease.</p></fn><fn id="table-fn4-1179548418771702"><label>*</label><p><italic>P&#x02009;</italic>&#x0003c;&#x02009;.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section9-1179548418771702"><title>Lung function and COPD control according to fluticasone dose</title><p>Treatment with either dose of fluticasone in combination with salmeterol improved FEV<sub>1</sub> and CAT (<xref ref-type="table" rid="table2-1179548418771702">Table 2</xref>). There was no inspiratory capacity change in either treatment group. During the 12-month period, approximately equal numbers of patients experienced exacerbations in the 2 groups (35.0% in the 250&#x02009;&#x000b5;g group and 28.2% in the 100&#x02009;&#x000b5;g group, <italic>P</italic>&#x02009;=&#x02009;.22). The percentages of patients with more than 2 exacerbations per year were 12.2% in the 250&#x02009;&#x000b5;g group and 7.7% in the 100&#x02009;&#x000b5;g group with no significant difference between them. There was also no difference in the proportion of patients with severe exacerbations between the 2 groups (9.4% in the 250&#x02009;&#x000b5;g group and 9.0% in the 100&#x02009;&#x000b5;g group, <italic>P</italic>&#x02009;=&#x02009;.67). There was no death in the 2 groups during the observation period.</p><table-wrap id="table2-1179548418771702" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Pulmonary function and COPD assessment test scores before and after combination treatment with fluticasone propionate and salmeterol.</p></caption><alternatives><graphic xlink:href="10.1177_1179548418771702-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Fluticasone propionate100&#x02009;&#x000b5;g and salmeterol (n&#x02009;=&#x02009;78)<hr/></th><th align="center" colspan="2" rowspan="1">Fluticasone propionate 250&#x02009;&#x000b5;g and salmeterol (n&#x02009;=&#x02009;180)<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">After</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">After</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>FVC (L)</bold>
</td><td rowspan="1" colspan="1">2.64 (1.23-4.12)</td><td rowspan="1" colspan="1">2.80 (0.73-4.24)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">*</xref></td><td rowspan="1" colspan="1">2.54 (1.21-4.84)</td><td rowspan="1" colspan="1">2.67 (1.16-4.90)</td></tr><tr><td rowspan="1" colspan="1">
<bold>FEV<sub>1</sub> (L)</bold>
</td><td rowspan="1" colspan="1">1.18 (0.63-2.04)</td><td rowspan="1" colspan="1">1.31 (0.60-2.24)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">**</xref></td><td rowspan="1" colspan="1">1.16 (0.40-2.85)</td><td rowspan="1" colspan="1">1.18 (0.36-3.25)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">**</xref></td></tr><tr><td rowspan="1" colspan="1">
<bold>FEV<sub>1</sub>, % predicted (%)</bold>
</td><td rowspan="1" colspan="1">56.9 (23.1-143.2)</td><td rowspan="1" colspan="1">58.7 (25.0-165.9)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">**</xref></td><td rowspan="1" colspan="1">55.1 (20.0-122.1)</td><td rowspan="1" colspan="1">57.3 (18.4-130.8)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">**</xref></td></tr><tr><td rowspan="1" colspan="1"><bold>FEV<sub>1</sub>/</bold>FVC (%)</td><td rowspan="1" colspan="1">46.1 (27.5-69.5)</td><td rowspan="1" colspan="1">47.8 (24.9-99.3)</td><td rowspan="1" colspan="1">46.0 (17.9-68.0)</td><td rowspan="1" colspan="1">45.1 (26.2-76.2)</td></tr><tr><td rowspan="1" colspan="1">Inspiratory Capacity (L)</td><td rowspan="1" colspan="1">1.77 (0.87-3.08)</td><td rowspan="1" colspan="1">1.83 (0.97-2.74)</td><td rowspan="1" colspan="1">1.77 (0.31-3.72)</td><td rowspan="1" colspan="1">1.76 (0.61-3.81)</td></tr><tr><td rowspan="1" colspan="1">
<bold>CAT</bold>
</td><td rowspan="1" colspan="1">11 (1-35)</td><td rowspan="1" colspan="1">9 (0-35)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">*</xref></td><td rowspan="1" colspan="1">13 (2-33)</td><td rowspan="1" colspan="1">11 (1-33)<xref ref-type="table-fn" rid="table-fn7-1179548418771702">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-1179548418771702"><p>Abbreviations: CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1&#x02009;second; FVC, forced vital capacity.</p></fn><fn id="table-fn6-1179548418771702"><p>Values are expressed as median (range).</p></fn><fn id="table-fn7-1179548418771702"><label>*</label><p><italic>P&#x02009;</italic>&#x0003c;&#x02009;.05 <italic>versus</italic> baseline; **<italic>P&#x02009;</italic>&#x0003c;&#x02009;.01 <italic>versus</italic> baseline.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section10-1179548418771702"><title>Adverse events</title><p>Major adverse events are shown in <xref ref-type="table" rid="table3-1179548418771702">Table 3</xref>. Incidence of any adverse event in the 250 and 100&#x02009;&#x000b5;g groups were 22.2% and 18.0%, respectively. The most common toxicity was oral cavity or pharynx problems and the incidence of both was approximately equal. The incidence of lower respiratory tract infection was much higher in the 250&#x02009;&#x000b5;g group than in the 100&#x02009;&#x000b5;g group (9.4% vs 1.3%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;.01). During the follow-up period, fluticasone treatment was withdrawn in 5 patients (6.5%) in the 100&#x02009;&#x000b5;g group and 9 (6.4%) in the 250&#x02009;&#x000b5;g group due to oral cavity problems. In addition, fluticasone was withdrawn in 7 patients (3.9%) in the 250&#x02009;&#x000b5;g group after development of pneumonia, meaning a total of 16 patients discontinued treatment with fluticasone in this group. Univariate logistic regression analysis was carried out to estimate the predictive factors for the development of pneumonia using patient characteristics, spirometric data, and treatment as the variables (<xref ref-type="table" rid="table4-1179548418771702">Table 4</xref>). A low body mass index (BMI&#x02009;&#x0003c;&#x02009;20) and the use of fluticasone propionate 250&#x02009;&#x000b5;g were significantly associated with pneumonia development (odds ratio, 5.10; 95% confidence interval [CI], 1.75-18.5; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.01, odds ratio, 7.51; 95% CI, 1.49-136.7; <italic>P</italic>&#x02009;=&#x02009;.01, respectively).</p><table-wrap id="table3-1179548418771702" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Adverse events during treatment with fluticasone propionate and salmeterol.</p></caption><alternatives><graphic xlink:href="10.1177_1179548418771702-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Fluticasone propionate 100&#x02009;&#x000b5;g and salmeterol</th><th align="center" rowspan="1" colspan="1">Fluticasone propionate 250&#x02009;&#x000b5;g and salmeterol</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Patients with adverse events</td><td rowspan="1" colspan="1">14 (18.0%)</td><td rowspan="1" colspan="1">40 (22.2%)</td></tr><tr><td rowspan="1" colspan="1">Problems of oral cavity</td><td rowspan="1" colspan="1">11 (14.1%)</td><td rowspan="1" colspan="1">20 (11.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hoarseness</td><td rowspan="1" colspan="1">8 (10.3%)</td><td rowspan="1" colspan="1">15 (8.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Throat irritation</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">3 (1.7%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dry mouth</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">2 (1.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Aphthous ulcer</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">1 (0.6%)</td></tr><tr><td rowspan="1" colspan="1">Lower tract infections</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">17 (9.4%)<xref ref-type="table-fn" rid="table-fn8-1179548418771702">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pneumonia</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">16 (8.9%)<xref ref-type="table-fn" rid="table-fn8-1179548418771702">**</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pulmonary tuberculosis</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">1 (0.6%)</td></tr><tr><td rowspan="1" colspan="1">Others</td><td rowspan="1" colspan="1">2 (2.6%)</td><td rowspan="1" colspan="1">3 (1.7%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Heartburn</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">2 (1.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Urticaria</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">1 (0.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dysuria</td><td rowspan="1" colspan="1">1 (1.3%)</td><td rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn8-1179548418771702"><label>*</label><p><italic>P</italic>&#x02009;&#x0003c;&#x02009;.01, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 difference according to fluticasone propionate dose.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table4-1179548418771702" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Univariate and multivariate logistic analyses of risk factors for developing pneumonia.</p></caption><alternatives><graphic xlink:href="10.1177_1179548418771702-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Factor</th><th align="center" colspan="3" rowspan="1">Univariate logistic analysis<hr/></th><th align="center" colspan="3" rowspan="1">Multivariate logistic analysis<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Odds ratio</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">Odds ratio</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, &#x0003e;65&#x02009;y</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">0.26-3.74</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1.21</td><td rowspan="1" colspan="1">0.23-22.6</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Body mass index, &#x0003c;20&#x02009;kg/m<sup>2</sup></td><td rowspan="1" colspan="1">5.10</td><td rowspan="1" colspan="1">1.75-18.5</td><td rowspan="1" colspan="1">&#x0003c;&#x02009;0.01</td><td rowspan="1" colspan="1">4.88</td><td rowspan="1" colspan="1">1.63-18.0</td><td rowspan="1" colspan="1">&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">Current smoker</td><td rowspan="1" colspan="1">0.37</td><td rowspan="1" colspan="1">0.02-1.88</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Acute exacerbation in the previous year</td><td rowspan="1" colspan="1">2.02</td><td rowspan="1" colspan="1">0.71-5.49</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">1.65</td><td rowspan="1" colspan="1">0.55-4.68</td><td rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.15-3.85</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">0.14-3.97</td><td rowspan="1" colspan="1">0.96</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub> %pred, &#x0003c;50%</td><td rowspan="1" colspan="1">1.62</td><td rowspan="1" colspan="1">0.58-4.54</td><td rowspan="1" colspan="1">0.35</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CAT<sup>a</sup>, &#x02265;10 point</td><td rowspan="1" colspan="1">1.93</td><td rowspan="1" colspan="1">0.47-13.0</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">The use of fluticasone propionate, 250&#x02009;&#x000b5;g</td><td rowspan="1" colspan="1">7.51</td><td rowspan="1" colspan="1">1.49-136.7</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">7.91</td><td rowspan="1" colspan="1">1.54-145.0</td><td rowspan="1" colspan="1">&#x0003c;&#x02009;0.01</td></tr><tr><td rowspan="1" colspan="1">The use of long-acting muscarinic antagonist</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">0.32-3.44</td><td rowspan="1" colspan="1">0.92</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn9-1179548418771702"><p>Abbreviations: CAT, COPD assessment test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1&#x02009;second.</p></fn><fn id="table-fn10-1179548418771702"><label>a</label><p>Combined COPD assessment proposed by Global Initiative for Chronic Obstructive Lung Disease.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section11-1179548418771702"><title>Discussion</title><p>In the present study, treatment with 250 and 100&#x02009;&#x000b5;g fluticasone propionate in combination with salmeterol twice daily improved pulmonary function, symptoms, and health status. There was no significant difference in frequency of exacerbations between the 2 doses of fluticasone. However, patients in the 250&#x02009;&#x000b5;g group experienced pneumonia more frequently. Although this study did not determine the implications of using inhaled corticosteroids in COPD treatment, it suggests that the beneficial effects of inhaled corticosteroids might occur at even lower doses than those currently used.</p><p>Most COPD treatments target bronchodilation, with the aim of relieving bronchoconstriction and improving respiratory distress and exercise tolerance.<sup><xref rid="bibr2-1179548418771702" ref-type="bibr">2</xref><xref rid="bibr3-1179548418771702" ref-type="bibr"/><xref rid="bibr4-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr5-1179548418771702" ref-type="bibr">5</xref></sup> However, this strategy does not increase survival.<sup><xref rid="bibr6-1179548418771702" ref-type="bibr">6</xref></sup> In contrast with bronchial asthma, airway inflammation in COPD is mainly due to neutrophil inflammation, not eosinophil inflammation, which reduces the benefits of corticosteroids in COPD treatment.<sup><xref rid="bibr22-1179548418771702" ref-type="bibr">22</xref></sup> At present, addition of inhaled corticosteroids to long-acting bronchodilators is recommended for patients at high risk of exacerbations and with a history of frequent exacerbation events and severe obstructive respiratory events.<sup><xref rid="bibr4-1179548418771702" ref-type="bibr">4</xref>,<xref rid="bibr5-1179548418771702" ref-type="bibr">5</xref></sup> However, the use of inhaled corticosteroids in COPD is controversial. Recently, continued use of inhaled corticosteroids was evaluated in 2485 patients with severe or very severe COPD.<sup><xref rid="bibr23-1179548418771702" ref-type="bibr">23</xref></sup> In this Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM) trial, patients received triple therapy with tiotropium, salmeterol, and 500&#x02009;&#x000b5;g fluticasone twice daily. They were then randomly assigned to withdrawal from fluticasone or continuation of triple therapy to determine the effects of the inhaled corticosteroid. The reduction in trough FEV<sub>1</sub> was greater in the withdrawal group at week 18 when fluticasone withdrawal was completed. However, the risk of moderate or severe exacerbations was comparable between both groups. In another study, which investigated the effect of switching from combined fluticasone propionate 500&#x02009;&#x000b5;g and salmeterol 50&#x02009;&#x000b5;g twice daily to indacaterol monotherapy, there was no efficacy loss for trough FEV<sub>1</sub> or exacerbation rate.<sup><xref rid="bibr24-1179548418771702" ref-type="bibr">24</xref></sup> As for the combination of a long-acting anticholinergic and a &#x003b2;<sub>2</sub> agonist, the Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations (FLAME) trial showed the combination of indacaterol and glycopyrronium was more effective than salmeterol and 500&#x02009;&#x000b5;g fluticasone in reduction of the annual exacerbation rate.<sup><xref rid="bibr25-1179548418771702" ref-type="bibr">25</xref></sup> Regarding safety, Suissa et al evaluated health insurance databases and showed that discontinuation of inhaled corticosteroids reduced the elevated risk of severe pneumonia.<sup><xref rid="bibr18-1179548418771702" ref-type="bibr">18</xref></sup> Risk reduction by discontinuing inhaled corticosteroids was 37%, and this was more significant in cases with fluticasone. Taking into account the clinical risk&#x02013;benefit profile of fluticasone, it may be advisable to discontinue fluticasone therapy in COPD.</p><p>However, adding inhaled corticosteroids to bronchodilator might nevertheless contribute certain benefits, such as preventing exacerbations and slowing pulmonary function decline .<sup><xref rid="bibr6-1179548418771702" ref-type="bibr">6</xref>,<xref rid="bibr10-1179548418771702" ref-type="bibr">10</xref>,<xref rid="bibr26-1179548418771702" ref-type="bibr">26</xref>,<xref rid="bibr27-1179548418771702" ref-type="bibr">27</xref></sup> In COPD, pneumonia is much less common than exacerbations.<sup><xref rid="bibr28-1179548418771702" ref-type="bibr">28</xref></sup> Despite the increased risk of pneumonia, the use of inhaled corticosteroids is not associated with all-cause mortality, which might suggest that their adverse effects are not observed consistently.<sup><xref rid="bibr18-1179548418771702" ref-type="bibr">18</xref></sup> Indeed, some subsets of patients with COPD, such as those with blood eosinophilia<sup><xref rid="bibr29-1179548418771702" ref-type="bibr">29</xref></sup> or asthma&#x02013;COPD overlap syndrome, might respond well to inhaled corticosteroids. And there is the possibility that even lower doses of inhaled corticosteroids may provide therapeutic benefit without increasing the risk of pneumonia, as this was related to the daily dose of inhaled corticosteroid. In a retrospective cohort analysis using claims databases, the incidence of pneumonia with low (1-499&#x02009;&#x000b5;g), medium (500-999&#x02009;&#x000b5;g), and high (&#x0003e;1000&#x02009;&#x000b5;g) doses of inhaled corticosteroids (doses equivalent to daily fluticasone propionate) was 0.150, 0.247, and 0.319, respectively.<sup><xref rid="bibr20-1179548418771702" ref-type="bibr">20</xref></sup> Although fluticasone 500&#x02009;&#x000b5;g in combination with salmeterol 50&#x02009;&#x000b5;g twice daily is widely used for treating COPD, few trials have investigated appropriate doses for this indication. Some clinical studies used inhaled corticosteroids at 250&#x02009;&#x000b5;g,<sup><xref rid="bibr14-1179548418771702" ref-type="bibr">14</xref><xref rid="bibr15-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr16-1179548418771702" ref-type="bibr">16</xref></sup> but the efficacy and safety of 100&#x02009;&#x000b5;g fluticasone propionate remained unclear. We therefore evaluated the benefit of lower doses of fluticasone propionate in the present retrospective study. There were no significant differences in lung function, health status, or exacerbations between the 100 and 250&#x02009;&#x000b5;g doses of fluticasone propionate examined in the present study. The incidence of pneumonia in patients receiving 250&#x02009;&#x000b5;g fluticasone propionate was 8.9%, almost identical to that reported in previous studies.<sup><xref rid="bibr14-1179548418771702" ref-type="bibr">14</xref><xref rid="bibr15-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr16-1179548418771702" ref-type="bibr">16</xref></sup> Conversely, the risk of pneumonia was much lower in patients receiving 100&#x02009;&#x000b5;g fluticasone propionate.</p><p>Crim et al<sup><xref rid="bibr30-1179548418771702" ref-type="bibr">30</xref></sup> identified risk factors for pneumonia in a post hoc analysis of the TORCH study. Older age (&#x0003e;55&#x02009;years), lower predicted FEV<sub>1</sub> (&#x0003c;50%), exacerbation(s) in the preceding year, worse dyspnea score, and lower BMI (&#x0003c;20) were significantly associated with the probability of pneumonia. In the present study, logistic regression analyses were performed using similar factors and BMI&#x02009;&#x0003c;&#x02009;20 and the use of fluticasone propionate 250&#x02009;&#x000b5;g were significantly associated with the development of pneumonia in univariate and multivariate analyses.</p><p>This was a retrospective study and there were a number of confounding factors. The dose of fluticasone propionate was selected at the discretion of the treating physicians, which can induce bias as more severe cases tend to receive larger doses. Furthermore, the diagnosis of pneumonia was important in this retrospective study. To date, many clinical trials have demonstrated that patients receiving inhaled corticosteroid-containing treatments had an increased risk of pneumonia.<sup><xref rid="bibr17-1179548418771702" ref-type="bibr">17</xref><xref rid="bibr18-1179548418771702" ref-type="bibr"/><xref rid="bibr19-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr20-1179548418771702" ref-type="bibr">20</xref>,<xref rid="bibr27-1179548418771702" ref-type="bibr">27</xref>,<xref rid="bibr28-1179548418771702" ref-type="bibr">28</xref>,<xref rid="bibr30-1179548418771702" ref-type="bibr">30</xref></sup> But in most of those studies, the objective definitions of pneumonia were not determined and the diagnosis was defined clinically, not radiographically.<sup><xref rid="bibr17-1179548418771702" ref-type="bibr">17</xref><xref rid="bibr18-1179548418771702" ref-type="bibr"/><xref rid="bibr19-1179548418771702" ref-type="bibr"/>&#x02013;<xref rid="bibr20-1179548418771702" ref-type="bibr">20</xref>,<xref rid="bibr27-1179548418771702" ref-type="bibr">27</xref>,<xref rid="bibr30-1179548418771702" ref-type="bibr">30</xref></sup> Pneumonia has a high degree of clinical overlap with COPD exacerbations. Without a chest radiograph, it can be difficult to distinguish between pneumonia and exacerbation.<sup><xref rid="bibr28-1179548418771702" ref-type="bibr">28</xref></sup> In the present study, we confirmed pneumonia using a chest X-ray or computed tomography. Our study showed that patients receiving a higher dose of fluticasone propionate developed a higher percentage of radiographically confirmed pneumonia in comparison with patients using a lower dose of fluticasone propionate. Second, because we included only patients receiving fluticasone&#x02013;salmeterol combination inhaler, the effect of other inhaler corticosteroids remains unclear. Improvements in pulmonary function might be solely due to use of salmeterol in both groups. Third, this study did not determine the validity and implications of using inhaled corticosteroids in COPD treatment. Considering the GOLD combined COPD assessment grades, a large proportion of included patients did not have an indication for inhaled corticosteroids. This was a retrospective study without defined treatment protocol, which might reflect real-world clinical practice. Price et al<sup><xref rid="bibr12-1179548418771702" ref-type="bibr">12</xref></sup> reported that inhaled corticosteroids were widely prescribed outside guideline recommendations in the United Kingdom.</p></sec><sec sec-type="conclusions" id="section12-1179548418771702"><title>Conclusions</title><p>Treatment with 100&#x02009;&#x000b5;g fluticasone propionate in combination with salmeterol showed similar improvements in pulmonary function, symptoms, and health status to 250&#x02009;&#x000b5;g fluticasone propionate, but the risk of pneumonia was lower in patients receiving the lower dose. Although it was a retrospective analysis with confounding factors, these results warrant further investigation in prospective trials to evaluate the effect and safety of low-dose inhaled corticosteroids, such as 100&#x02009;&#x000b5;g fluticasone propionate, in the treatment of COPD.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Author Contributions:</bold> HY, NI, and TS conceived and designed the experiments. HY, TF, MK, and NE analyzed the data. HY, NI, and TS wrote the first draft of the manuscript. YN, SK, HO, KY, JS, MS, NK, MT, TY, MM, and TS contributed to the writing of the manuscript. All authors agreed with manuscript results and conclusions, reviewed, and approved the final manuscript.</p></fn><fn fn-type="other"><p><bold>Disclosures and Ethics:</bold> The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration Of Conflicting Interests:</bold>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1179548418771702"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>:<fpage>2095</fpage>&#x02013;<lpage>2128</lpage>.<pub-id pub-id-type="pmid">23245604</pub-id></mixed-citation></ref><ref id="bibr2-1179548418771702"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper</article-title>. <source>Eur Respir J</source>. <year>2004</year>;<volume>23</volume>:<fpage>932</fpage>&#x02013;<lpage>946</lpage>.<pub-id pub-id-type="pmid">15219010</pub-id></mixed-citation></ref><ref id="bibr3-1179548418771702"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>176</volume>:<fpage>532</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">17507545</pub-id></mixed-citation></ref><ref id="bibr4-1179548418771702"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name><name><surname>Agusti</surname><given-names>AG</given-names></name><etal>et al</etal></person-group>
<article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2013</year>;<volume>187</volume>:<fpage>347</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">22878278</pub-id></mixed-citation></ref><ref id="bibr5-1179548418771702"><label>5</label><mixed-citation publication-type="web"><article-title>Global strategy for the diagnosis management prevention of chronic obstructive lung disease</article-title>, <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org">http://www.goldcopd.org</ext-link>. <comment>Accessed May 20, 2014</comment>.</mixed-citation></ref><ref id="bibr6-1179548418771702"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>:<fpage>775</fpage>&#x02013;<lpage>789</lpage>.<pub-id pub-id-type="pmid">17314337</pub-id></mixed-citation></ref><ref id="bibr7-1179548418771702"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Bhowmik</surname><given-names>A</given-names></name><name><surname>Wedzicha</surname><given-names>JA.</given-names></name></person-group>
<article-title>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>. <year>2002</year>;<volume>57</volume>:<fpage>847</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">12324669</pub-id></mixed-citation></ref><ref id="bibr8-1179548418771702"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Jones</surname><given-names>PW.</given-names></name></person-group>
<article-title>Impact of preventing exacerbations on deterioration of health status in COPD</article-title>. <source>Eur Respir J</source>. <year>2004</year>;<volume>23</volume>:<fpage>698</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="pmid">15176682</pub-id></mixed-citation></ref><ref id="bibr9-1179548418771702"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soler-Cataluna</surname><given-names>JJ</given-names></name><name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name><name><surname>Roman Sanchez</surname><given-names>P</given-names></name><name><surname>Salcedo</surname><given-names>E</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Ochando</surname><given-names>R.</given-names></name></person-group>
<article-title>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>. <year>2005</year>;<volume>60</volume>:<fpage>925</fpage>&#x02013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">16055622</pub-id></mixed-citation></ref><ref id="bibr10-1179548418771702"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>IA</given-names></name><name><surname>Clarke</surname><given-names>MS</given-names></name><name><surname>Sim</surname><given-names>EHA</given-names></name><name><surname>Fong</surname><given-names>KM.</given-names></name></person-group>
<article-title>Inhaled corticosteroids for stable chronic obstructive pulmonary disease</article-title>. <source>Cochrane Db Syst Rev</source>. <year>2012</year>;<volume>2</volume>: <fpage>CD002991</fpage>.</mixed-citation></ref><ref id="bibr11-1179548418771702"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Leather</surname><given-names>D</given-names></name><name><surname>Bakerly</surname><given-names>ND</given-names></name><etal>et al</etal></person-group>
<article-title>Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>1253</fpage>&#x02013;<lpage>1260</lpage>.<pub-id pub-id-type="pmid">27593504</pub-id></mixed-citation></ref><ref id="bibr12-1179548418771702"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Pavord</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis</article-title>. <source>NPJ Prim Care Respir Med</source>. <year>2016</year>;<volume>26</volume>:<fpage>16061</fpage>.<pub-id pub-id-type="pmid">27808096</pub-id></mixed-citation></ref><ref id="bibr13-1179548418771702"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sin</surname><given-names>DD</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><etal>et al</etal></person-group>
<article-title>Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>. <year>2005</year>;<volume>60</volume>:<fpage>992</fpage>&#x02013;<lpage>997</lpage>.<pub-id pub-id-type="pmid">16227327</pub-id></mixed-citation></ref><ref id="bibr14-1179548418771702"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Darken</surname><given-names>P</given-names></name><name><surname>Horstman</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the diskus inhaler for the treatment of COPD</article-title>. <source>Chest</source>. <year>2003</year>;<volume>124</volume>:<fpage>834</fpage>&#x02013;<lpage>843</lpage>.<pub-id pub-id-type="pmid">12970006</pub-id></mixed-citation></ref><ref id="bibr15-1179548418771702"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Fei</surname><given-names>R</given-names></name><name><surname>Emmett</surname><given-names>A</given-names></name><name><surname>Knobil</surname><given-names>K</given-names></name><name><surname>Kalberg</surname><given-names>C.</given-names></name></person-group>
<article-title>Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations</article-title>. <source>Respir Med</source>. <year>2008</year>;<volume>102</volume>:<fpage>1099</fpage>&#x02013;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">18614347</pub-id></mixed-citation></ref><ref id="bibr16-1179548418771702"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Feldman</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes</article-title>. <source>COPD</source>. <year>2009</year>;<volume>6</volume>:<fpage>320</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">19863361</pub-id></mixed-citation></ref><ref id="bibr17-1179548418771702"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ernst</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>AV</given-names></name><name><surname>Brassard</surname><given-names>P</given-names></name><name><surname>Suissa</surname><given-names>S.</given-names></name></person-group>
<article-title>Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia</article-title>. <source>Am J Resp Crit Care</source>. <year>2007</year>;<volume>176</volume>:<fpage>162</fpage>&#x02013;<lpage>166</lpage>.</mixed-citation></ref><ref id="bibr18-1179548418771702"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suissa</surname><given-names>S</given-names></name><name><surname>Patenaude</surname><given-names>V</given-names></name><name><surname>Lapi</surname><given-names>F</given-names></name><name><surname>Ernst</surname><given-names>P.</given-names></name></person-group>
<article-title>Inhaled corticosteroids in COPD and the risk of serious pneumonia</article-title>. <source>Thorax</source>. <year>2013</year>;<volume>68</volume>:<fpage>1029</fpage>&#x02013;<lpage>1036</lpage>.<pub-id pub-id-type="pmid">24130228</pub-id></mixed-citation></ref><ref id="bibr19-1179548418771702"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yawn</surname><given-names>BP</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Arcona</surname><given-names>S</given-names></name><name><surname>Kahler</surname><given-names>KH.</given-names></name></person-group>
<article-title>Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>. <year>2013</year>;<volume>8</volume>:<fpage>295</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">23836970</pub-id></mixed-citation></ref><ref id="bibr20-1179548418771702"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aaron</surname><given-names>SD</given-names></name><name><surname>Vandemheen</surname><given-names>KL</given-names></name><name><surname>Fergusson</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</article-title>. <source>Ann Intern Med</source>. <year>2007</year>;<volume>146</volume>:<fpage>545</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">17310045</pub-id></mixed-citation></ref><ref id="bibr21-1179548418771702"><label>21</label><mixed-citation publication-type="book"><source>Guidelines of Respiratory Function Tests: Spirometry, Flow-Volume Curve, and Diffusion Capacity of the Lung</source> (ed. <collab>the Japanese Respiratory Society</collab>). <publisher-loc>Tokyo, Japan</publisher-loc>: <publisher-name>Japanese Respiratory Society</publisher-name>; <year>2004</year>.</mixed-citation></ref><ref id="bibr22-1179548418771702"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>McKenna</surname><given-names>S</given-names></name><name><surname>Hargadon</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>. <year>2005</year>;<volume>60</volume>:<fpage>193</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">15741434</pub-id></mixed-citation></ref><ref id="bibr23-1179548418771702"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Magnussen</surname><given-names>H</given-names></name><name><surname>Disse</surname><given-names>B</given-names></name><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Withdrawal of inhaled glucocorticoids and exacerbations of COPD</article-title>. <source>New Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>1285</fpage>&#x02013;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">25196117</pub-id></mixed-citation></ref><ref id="bibr24-1179548418771702"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>van der Molen</surname><given-names>T</given-names></name><name><surname>del Olmo</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD</article-title>. <source>Eur Respir J</source>. <year>2014</year>;<volume>44</volume>:<fpage>1548</fpage>&#x02013;<lpage>1556</lpage>.<pub-id pub-id-type="pmid">25359348</pub-id></mixed-citation></ref><ref id="bibr25-1179548418771702"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Banerji</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><etal>et al</etal></person-group>
<article-title>Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>374</volume>:<fpage>2222</fpage>&#x02013;<lpage>2234</lpage>.<pub-id pub-id-type="pmid">27181606</pub-id></mixed-citation></ref><ref id="bibr26-1179548418771702"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Pauwels</surname><given-names>R</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>361</volume>:<fpage>449</fpage>&#x02013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">12583942</pub-id></mixed-citation></ref><ref id="bibr27-1179548418771702"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Restrepo</surname><given-names>MI</given-names></name><name><surname>Fine</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group>
<article-title>Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2011</year>;<volume>184</volume>:<fpage>312</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">21512168</pub-id></mixed-citation></ref><ref id="bibr28-1179548418771702"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Seemungal</surname><given-names>TAR</given-names></name><etal>et al</etal></person-group>
<article-title>Reported pneumonia in patients with COPD findings from the INSPIRE study</article-title>. <source>Chest</source>. <year>2011</year>;<volume>139</volume>:<fpage>505</fpage>&#x02013;<lpage>512</lpage>.<pub-id pub-id-type="pmid">20576732</pub-id></mixed-citation></ref><ref id="bibr29-1179548418771702"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Kolsum</surname><given-names>U</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><etal>et al</etal></person-group>
<article-title>Eosinophilic inflammation in COPD: prevalence and clinical characteristics</article-title>. <source>Eur Respir J</source>. <year>2014</year>;<volume>44</volume>:<fpage>1697</fpage>&#x02013;<lpage>1700</lpage>.<pub-id pub-id-type="pmid">25323230</pub-id></mixed-citation></ref><ref id="bibr30-1179548418771702"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crim</surname><given-names>C</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><etal>et al</etal></person-group>
<article-title>Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results</article-title>. <source>Eur Respir J</source>. <year>2009</year>;<volume>34</volume>:<fpage>641</fpage>&#x02013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">19443528</pub-id></mixed-citation></ref></ref-list></back></article>